The middle-sized (M) surface proteins of hepatitis B virus (HBV) and other orthohepadnaviruses contain a conserved N-glycan in their pre-S2 domain, which is essential for the secretion of viral particles. Recently, we also found O-glycans in the pre-S2 domain of M protein from woodchuck hepatitis virus (WHV) and HBV genotype D. Since the O-glycosylation motif is not conserved in all genotypes of HBV, the glycosylation patterns of HBV genotypes A and C were analysed. Pre-S2 (glyco)peptides were released from HBV-carrier-derived HBV subviral particles by tryptic digestion, purified by reversed-phase HPLC and identified by amino acid and amino-terminal sequence analysis as well as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Pre-S2 N-glycans were characterized by anion-exchange chromatography, methylation analysis and on-target sequential exoglycosidase digestions in combination with MALDI-TOF-MS, demonstrating the presence of partially sialylated diantennary complex-type oligosaccharides in all genotypes examined. Pre-S2 O-glycans were characterized by on-target sequential exoglycosidase digestions in combination with MALDI-TOF-MS. The pre-S2 domain of M protein and, to a minor extent, of L (large) protein from HBV genotype C and D was partially O-glycosylated by Neu5Ac(a2-3)Gal(b1-3)GalNAca-or Gal(b1-3)GalNAca-units at Thr-37 within a conserved sequence context. Genotype A, containing no Thr at position 37 or 38, was not O-glycosylated. Analytical data further revealed that M protein is mostly amino-terminally acetylated in all examined genotypes and that the terminal methionine is partially oxidized. The findings may be relevant for the secretion and the immunogenicity of HBV.
INTRODUCTION
Chronic hepatitis B virus (HBV) infection may lead to liver cirrhosis and hepatocellular carcinoma and results in about one million deaths per year worldwide. The virus replicates in the liver and is secreted into the blood. In addition to complete virions, infected hepatocytes produce subviral 22 nm spherical or filamentous particles in vast excess (Ganem & Schneider, 2001; Hollinger & Liang, 2001; Kann & Gerlich, 1998) . Virions and subviral particles contain varying proportions of three co-carboxy-terminal HBVencoded (glyco) proteins (Fig. 1a) , termed large (L), middle (M) and small (S) proteins, which together are referred to as HBV surface antigen (HBsAg). S protein is the major component of the virion envelope and HBsAg particles, whilst filaments and virions contain more L proteins than spheres (Heermann et al., 1984) . The amino-terminal pre-S1 domain of HBsAg occurs exclusively in the L protein and the pre-S2 domain is present in both M and L proteins, whereas the S domain is common to S, M and L proteins. All three proteins possess a potential N-glycosylation site at Asn-146 of the S domain; however, this is only partially utilized. Hence, the proteins exist in two isomeric forms, being either glycosylated or non-glycosylated in this position, and migrate as doublets in SDS-PAGE (Fig. 1b) . The second potential N-glycosylation site at Asn-4 of the pre-S2 domain is used only in the M but not in the L protein (Heermann et al., 1984) . In addition to N-glycosylation, pre-S2 domains of M proteins from HBV (Schmitt et al., 1999) as well as the related woodchuck hepatitis virus (WHV) (Tolle et al., 1998) are O-glycosylated.
The L, but not M protein, mediates binding to human
Additional experiments are supplied as supplementary data, available in JGV Online.
hepatocytes of the virus via its pre-S1 domain (Neurath et al., 1986b; Pontisso et al., 1989) and is essential for the infection of hepatocyte cultures Gripon et al., 2002) . Furthermore, the L, but not M protein, is important for virion envelopment and secretion (Bruss & Ganem, 1991) . In order to fulfil these functions, the pre-S domain of the L protein has a dual topology. During and directly after translation, it is located at the cytosolic side of the ER and, hence, within the virion after budding. Therefore, L is not N-glycosylated in its pre-S region. Later, L molecules change, in part, their topology by an unknown mechanism resulting in a surface exposure of their pre-S1 and pre-S2 sequences (Bruss et al., 1994) . In contrast, the pre-S2 domain of M protein is translocated co-translationally to the ER lumen and is, thus, N-glycosylated (Eble et al., 1990) .
The function of M protein is still not clear. However, M protein glycosylation at Asn-4 of pre-S2 and subsequent trimming of this N-glycan are important for the secretion of HBV (Block et al., 1994; Lu et al., 1995; Sheu & Lo, 1994) . Proper folding and trafficking of the M glycoprotein, assisted by calnexin in a carbohydrate-dependent manner (Mehta et al., 1997; Werr & Prange, 1998) , may support the assembly of virions. The pre-S2 N-glycan of the M protein has been considered as a promising target for antiviral therapy of hepatitis B, because viraemia could be suppressed by a-glucosidase I inhibitors in experimentally infected woodchucks (Block et al., 1998) .
Our previous studies on the pre-S2 N-glycan revealed the presence of partially sialylated diantennary complex-type oligosaccharides. Furthermore, Thr-37 of this protein is, in part, O-glycosylated by a Neu5Ac(a2-3)Gal(b1-3)GalNAca (sialyl-T-antigen), Gal(b1-3)GalNAca (Thomsen-Friedenreich antigen, T-antigen) or GalNAca residue (T n -antigen) (Schmitt et al., 1999) . O-glycosylation is more extensive in WHV M surface protein (Tolle et al., 1998) and in HBsAg particles secreted from non-hepatic cells (Werr & Prange, 1998) or in particles carrying certain pre-S2 deletions (Tai et al., 2002) . The exact structures of these O-glycans are not known.
The pre-S2 domain of HBsAg displays several T-and B-cell epitopes (Milich et al., 1990; Sobotta et al., 2000) , which are capable of inducing immune protection (Emini et al., 1989; Itoh et al., 1986; Neurath et al., 1986a) . Hence, M protein is a vaccine against HBV, which might (i) override non-responsiveness to the standard HBV vaccine consisting only of S protein (Zuckerman et al., 1997) , (ii) allow immunotherapeutic treatment of chronic HBV infections (Michel et al., 2001 ) and (iii) prevent selection of escape mutants with mutations in the S protein (Carman, 1997) . Hepatitis B vaccines containing pre-S2 have been generated in transfected yeast cells (DeWilde et al., 1991) , mouse fibroblasts (Young et al., 2001) or Chinese hamster ovary cells (Jungers et al., 1994; Leroux-Roels et al., 1997; Shapira et al., 2001; Young et al., 2001) , and studied with variable success in humans. Pre-S2-containing HBsAg from yeast cells was found to be heavily modified by O-glycans and virually ineffective as vaccine (DeWilde et al., 1991) . Studies on the O-glycosylation of pre-S2-containing vaccines expressed in rodent cell cultures have not been reported but, in view of the data observed by Werr & Prange (1998) and Tolle et al. (1998) , it is likely that these vaccines are also more strongly O-glycosylated than natural HBsAg.
The usefulness of the pre-S2 component in these vaccines is not yet proven, particularly because the anti-pre-S response induced by these vaccines in human recipients is rather (Bartholomeusz & Schaefer, 2004) . All contain an O-glycosylation motif around Thr-37 of pre-S2, but genotype A does not have this motif. In order to compare the in vivo pre-S2 glycosylation patterns of M protein from HBV genotypes A, C and D (Fig. 1c) , HBsAg particles were isolated from the plasma of chronically infected HBV carriers. Pre-S2 (glyco)peptides were released by trypsin digestion and subjected to carbohydrate structure analysis.
METHODS
Isolation of HBsAg. Subviral spherical and filamentous particles were purified from the sera of three chronically HBV-infected donors and quantified as described previously [for genotype D see Schmitt et al., (1999) ; for genotypes C and A see (Schaefer et al., 2003) .
Isolation of tryptic L and M protein-derived peptides.
Digestion of purified native HBsAg particles (between 1 and 4 mg) was carried out with trypsin as described previously (Schmitt et al., 1999) . In the case of genotype D, separation of tryptic peptides by reversed-phase HPLC was also carried out as published previously (Schmitt et al., 1999) , whereas peptides derived from genotypes C (2 mg) or A (1 mg) were separated employing slightly different conditions: C 18 -column (particle size 3 mm, pore size 9 nm, 2?16250 mm; MZ Analysentechnik), 0?1 % (v/v) aqueous trifluoroacetic acid (TFA) with an acetonitrile gradient (0-60 % in 60 min) and a flow rate of 120 ml min 21 at 28 uC.
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) of (glyco)peptides and released oligosaccharides. Molecular masses of rHPLC-purified peptides were determined on a Vision 2000 mass spectrometer (Finnigan MAT, Bremen). For analysis of released oligosaccharides, 50 or 15 pmol of glycans in aqueous solution was used for genotypes D and C or genotype A, respectively (Schmitt et al., 1999) . For external calibration of the peptide mass spectra, human angiotensin and bovine insulin (both from Sigma) or Sequazyme (Perseptive Biosystems) peptide mass standards were used.
Liberation of N-linked oligosaccharides from glycopeptides.
rHPLC fractions containing the N-glycosylated pre-S2 tryptic peptides (20 mg, i.e. about 10 nmol for genotype D) were digested with peptide-N 4 -(N-acetyl-b-glucosaminyl)asparagine amidase F (PNGase F) from Flavobacterium meningosepticum (Roche Molecular Biochemicals) as described previously (Schmitt et al., 1999) .
Glycopeptides derived from genotypes C (6?5 mg) and A (1?6 mg) were digested with recombinant PNGase F from Escherichia coli (Roche Molecular Biochemicals) as described above using 25 mU enzyme per mg substrate. Oligosaccharides were separated from peptide residues by rHPLC as described previously (Pfeiffer et al., 1993) .
High-pH anion-exchange chromatography (HPAEC). Separation of released oligosaccharides (genotype D 2 mg, genotype C 1 mg and genotype A 0?5 mg) was carried out at room temperature on a Dionex (Sunnyvale) BioLC system using a CarboPac PA-100 column (4?66250 mm) in series with a CarboPac PA guard column as described in detail previously (Schmitt et al., 1999) . A sodium acetate (210 mM) gradient (0-100 % in 48 min) in 100 mM NaOH was used at a flow rate of 1 ml min 21 . Oligosaccharides were monitored by pulsed amperometric detection, employing detection ranges of 300, 100 and 30 nA for genotypes D, C and A, respectively.
Peptide sequencing, carbohydrate constituent and methylation analysis, Western blotting, lectin analysis and immunostaining of HBsAg proteins, on-target sequential enzymic digestion of glycopeptides with glycosidases in combination with MALDI-TOF analysis, carboxypeptidase digestion of peptides and nano-LC-ESI-IT-MS and -MS/MS of glycopeptides are described in supplementary material in JGV Online.
RESULTS

Isolation of pre-S2 glycopeptides
HBV subviral particles were purified separately from sera of HBV carriers with genotypes D, C and A and incubated with trypsin. The S domain is highly resistant to trypsin, whereas (glyco)peptides of the pre-S region were released from the particles (Fig. 1a, c) . Resulting peptides were isolated by rHPLC (Fig. 2) . Peptides eluting in the interval of 32 to 50 min were identified by MALDI-TOF-MS and peptide sequencing. Compounds eluting prior to peptide 1 in Fig. 2 (a) could be neither registered by MALDI-TOF-MS nor characterized by amino acid or sequence analysis and were, therefore, assumed to represent non-peptide contaminants.
The amino-terminal pre-S2 tryptic peptide (aa 1-16; Fig. 1c ) was found by MALDI-TOF-MS analysis to be acetylated at the amino terminus to 90 % for genotype D, 100 % for C and >95 % for A, and therefore, was not directly accessible to Edman sequencing. In our previous study, the genotype D pre-S2 glycopeptide (1-16) has been identified by further digestion with chymotrypsin, subfractionation of the resulting peptides by rHPLC, detection of two internal fragments (9-12 and 13-16) by their molecular masses and assignment of a third peptide (4-8) by Edman degradation (Schmitt et al., 1999) . Here, the amino-terminal pre-S2 glycopeptides of genotypes C and A were discerned according to their retention times in rHPLC and their molecular masses determined by MALDI-TOF-MS. The original glycopeptides were eluted from the rHPLC column as several successive peaks (marked as A in Fig. 2 ) due to their heterogenity in glycosylation, acetylation and/or partial oxidation of the amino-terminal Met yielding methionine sulfoxide or methionine sulfone derivatives. As shown previously for HBV genotype D-derived pre-S2 glycopeptide (1-16) (Schmitt et al., 1999) , oxidation of Met-1 resulted in glycopeptide species comprising, in part, additional mass increments corresponding to one or two oxygen atoms (data not shown). In the present study, a similar degree of Met oxidation was registered by MALDI-TOF-MS in the case of genotype A glycopeptide (1-16), whereas the corresponding genotype C glycopeptides exhibited only methionine sulfoxide, and no methionine sulfone. It is not clear whether the oxidation of Met already occurs in vivo or reflects an artefact produced during sample handling. M protein was N-glycosylated to 100 % in the pre-S2 domain of all three genotypes examined, whereas the L protein was not substituted by carbohydrates in this position, as confirmed by analysis of the peptide (26-16; peptide B in Fig. 2 ).
Structural analysis of pre-S2 N-glycans
Pre-S2 N-glycans were released from the amino-terminal glycopeptides 1-16 by treatment with PNGase F and isolated by rHPLC. Neutral carbohydrate constituent analysis revealed a molar ratio of GlcNAc, Man and Gal of 3?4 : 3?0 : 2?2 for genotype D, 3?3 : 3?0 : 3?4 for genotype C and 3?6 : 3?0 : 1?6 for genotype A, which is typical for complex-type N-glycans. Sialic acid residues were not registered by the methods employed.
The presence of diantennary complex-type glycans (Galb4GlcNAcb2Mana3[Galb4GlcNAcb2Mana6]Manb4-GlcNAcb4GlcNAc) was substantiated for genotype D by sequential exoglycosidase digestion in combination with MALDI-TOF-MS and by methylation analysis for all three genotypes.
In order to determine the degree of sialylation, the released oligosaccharides were separated by HPAEC (Fig. 3) , which revealed differences in sialic acid substitution for the genotypes examined. N-Glycans of genotype D particles comprised disialylated (50 %), monosialylated (45 %) as well as unsialylated (5 %) oligosaccharide species, the latter of which were not found in the case of genotype C-and A-derived N-linked sugar chains. Instead, pre-S2 glycans from subviral particles of these genotypes were dominated by disialylated species, amounting to 88 (genotype C) and 93 % (genotype A) of total oligosaccharides. Hence, the N-glycans of the different genotypes examined differed in the degree of sialylation and, in part, in the linkage position of sialic acid.
Identification and structural analysis of pre-S2 O-glycans
The pre-S2 tryptic peptides 19-48 (Fig. 1c) , identified by amino acid analysis and Edman sequencing, were found to elute in four different peaks from the rHPLC column (Fig. 2a, peaks I , II, III and IV) in the case of genotype D, each of which displayed a different molecular mass in MALDI-TOF-MS (Schmitt et al., 1999) . HPLC separation of genotype C peptides revealed three related species (peaks I, II and IV in Fig. 2b ) comprising different masses as determined by mass spectrometry (data not shown) whereas, in the case of genotype A, only one compound (marked as IV in Fig. 2c ) with the mass of the unmodified peptide (19-48, Fig. 1c ) was found. The mass differences of glycopeptides from genotypes D and C were consistent with the mass increments of monosaccharide components such as HexNAc, Hex and Neu5Ac. Carbohydrate constituent analysis of the glycopeptides (i.e. peaks I, II and III in Fig. 2a and peaks I and II in Fig. 2b ) confirmed the peptides to be modified by an O-glycosidic-linked glycan, comprising GalNAc and Gal as neutral monosaccharide constituents. Sialic acid was not detectable by the procedure used. The extent of glycosylation was calculated from the peak areas in the rHPLC chromatogram (Fig. 2a, b) , demonstrating that for genotype D about 40 % of total peptides 19-48 were not O-glycosylated, 5 % contained only one T n -antigen, 30 % comprised the T-antigen and about 25 % exhibited the sialyl-T-antigen. For genotype C, glycosylation of this peptide amounted to 63 %, whereas peptides carrying the trisaccharide or disaccharide represented about 50 or 13 %, respectively. In contrast to corresponding genotype D-derived glycopeptides, a monosaccharidesubstituted peptide was not found.
To elucidate and compare the structures of the O-glycans of genotype D and C subviral particles, glycopeptides carrying the trisaccharide unit were treated sequentially with sialidase from Arthrobacter ureafaciens and O-glycosidase from Diplococcus pneumoniae, specifically releasing Gal(b1-3)GalNAca chains from Ser/Thr residues, directly on the MALDI target (Fig. 4) . Resulting products were analysed by MALDI-TOF-MS. The results revealed mass shifts of about 291 and 365 Da, reflecting the release of one sialic acid and one Gal(b1-3)GalNAca unit, respectively, yielding the molecular mass of the unsubstituted peptide. The glycopeptides containing only the disaccharide unit were similarly susceptible to digestion with O-glycosidase. Furthermore, the galactose residue could be removed by treatment with b-galactosidase from bovine testes, known to release preferentially (b1-3)-linked galactose (data not shown).
In order to verify these conclusions, the total O-glycopeptides of genotype D and C were subjected to methylation analysis, which demonstrated the presence of 3-substituted Gal and 3-substituted GalNAc in addition to terminal Gal originating from unsialylated glycopeptides (data not shown). Hence, the results supported the assignment that the structure of the sialylated glycan is Neu5Ac(a2-3)Gal(b1-3)GalNAca. The assumption that the reducing GalNAc residue is a-glycosidically linked is based on the reported substrate specificity of the enzyme O-glycosidase, whereas the b-anomeric configuration of galactosyl residues was confirmed by on-target digestion with b-galactosidase from bovine testes in combination with MALDI-TOF-MS (see above). Notably, sialic acid was found to be linked to C-3 of the subterminal Gal, although A. ureafaciens sialidase is known to release preferentially (a2-6)-linked sialic acid residues. Possibly, the kinetic properties of this enzyme are influenced by the presence of matrix during on-target digestion of the glycopeptide.
In order to allocate the observed O-glycans to M and/or L proteins, HBsAg filaments of genotypes A, C and D were separated by SDS-PAGE and either silver stained or subjected to blotting and lectin analysis or immunostaining (Fig. 5) , before and after treatment with A. ureafaciens sialidase alone or in combination with O-glycosidase, using peanut agglutinin (PNA), specifically binding the T-antigen, or a specific monoclonal anti-M protein antibody (Q19/10). Genotype A proteins did not react with PNA (Fig. 5a, part A) , confirming that this genotype is not O-glycosylated. Native genotype C and D M proteins (lanes Ø) exhibited only slight signals for lectin binding, which increased after digestion with sialidase (lanes S) and weakened strongly after additional treatment with O-glycosidase (lanes SO). The results for genotypes C and D revealed both M protein subspecies to be O-glycosylated. In contrast to our previous report (Schmitt et al., 1999) , clearly detectable binding of the lectin was also found with the L proteins from genotype D and more weakly with genotype C. This may be explained by more sensitive detection by the lectin. Monoclonal antibody Q19/10 recognition of M proteins was partly diminished after digestion with glycosidases in the case of genotypes A and C, suggesting a contribution of the sialic acid residues in the N-glycans to its epitope (Fig. 5b) . The presence of all HBsAg proteins in the preparation was verified by silver staining (Fig. 5c) . Treatment with sialidase decreased the size and heterogeneity of the M and L proteins in SDS-PAGE as expected.
Localization of the pre-S2 O-glycan
The sequences of the pre-S2 peptides (19-48) comprise seven Ser and three Thr residues in the case of genotypes D and C or seven Ser and one Thr residue in genotype A (Fig. 1c) . Using this information for prediction of the Oglycosylation site by the NetOGlyc 2.0 Prediction Server, which provides neural network predictions of mucin-type O-glycosylation sites in mammalian proteins (Hansen et al., 1998) , for genotype D, three Thr (Thr-31, -37 and -38) and two Ser residues (Ser-43 and -47) were proposed as potential O-glycosylation sites (Fig. 1c) , with Thr-37 having the highest potential of all. For genotype C, the same Thr residues, with Thr-38 having the highest score, and four Ser residues were predicted to be O-glycosylated, whereas, for genotype A, only Ser-43 was suggested as a potential O-glycosylation site. Similar results were obtained using the complete M protein sequences.
In order to identify the site of O-glycosylation chemically, glycopeptides I and II or I, II and III of the M proteins from genotypes C or D, respectively, as well as the nonglycosylated peptides IV (Figs 2a, b) were digested individually with carboxypeptidases. Resulting products were analysed by MALDI-TOF-MS. Treatment of the unglycosylated peptides 19-48 generated a ladder of signals due to the removal of between 1 and 20 aa. In the case of genotype D glycopeptides carrying the disaccharide or the trisaccharide, only up to 10 aa were removed, whereas the peptide substituted solely by GalNAc allowed the release of up to 11 aa (Schmitt et al., 1999) . In the case of the respective glycopeptides from genotype C virus, exhaustive carboxypeptidase digestion stopped after the removal of 9 aa (data not shown). These results pointed to Thr-37 for genotype D and Thr-38 for genotype C being, most likely, the O-glycosylation site, since the carboxypeptidases used release only unmodified amino acids from the carboxy terminus of peptides.
To substantiate further this assignment, the glycopeptide carrying the T-antigen derived from genotype D was studied by nanospray ESI-MS/MS analysis as reported earlier (Schmitt et al., 1999) , thus identifying Thr-37 as O-glycosylation site. In the case of rHPLC-purified pre-S2 glycopeptides (19-48) derived from genotype C virus, analogous nano-LC-ESI-IT-MS and -MS/MS analyses were performed, yielding similar results for glycopeptides carrying a Gal-GalNAc disaccharide or a Neu5Ac-Gal-GalNAc trisaccharide unit. Data obtained for the latter peptide are presented as a Supplementary Figure. Sufficient glycosylated species were recovered to allow the exclusive assignment of Thr-37 of the pre-S2 domain as glycosylation site.
DISCUSSION
Our analysis provides unambiguous information on the pre-S2 N-glycosylation of M protein obtained from patientderived HBsAg particles. All three genotypes studied contained partially sialylated, diantennary complex-type pre-S2 N-glycans. Observed differences were limited to the degree of sialylation and, in part, to the linkage position of the sialic acid. It is not clear, however, whether these differences are genotype-or host-specific or are, at least in part, because of naturally occurring desialylation, since the HBsAg particles used have been in serum for varying periods of time. In contrast to the literature on total N-linked glycans of HBsAg (Gillece-Castro et al., 1987) or on pre-S2 of cell culture-derived HBsAg (Mehta et al., 1997) , our analyses provided no evidence for the presence of fucosylated oligosaccharide species in genotype A, C and D HBsAg particles, suggesting that differences in fucosylation might reflect cell type-or site-specific variations in glycosylation.
Amino acid and sequence analyses as well as MALDI-TOF-MS of individual pre-S-derived (glyco)peptides revealed at least about 90 % of the M protein to be acetylated at the amino terminus. This acetylation of the amino terminus that is observed in all genotypes examined may protect against proteolytic degradation, which may be particularly relevant for the pre-S2 domain, which is known to be highly sensitive towards proteolysis (Stibbe & Gerlich, 1983) . In this context, it is interesting to note that M protein of WHV is not blocked at the amino terminus (Tolle et al., 1998) .
The third known post-translational modification of the pre-S2 domain comprises O-glycosylation. Genotypes C and D carry, at least in part, a single O-linked carbohydrate substituent, which could be identified as T n -antigen, Tantigen or sialyl-T-antigen. The degree of O-glycosylation in genotypes C and D differed in so far as that the genotype D in the M protein was glycosylated to a higher extent (63 %) than in the respective genotype C polypeptide (40 %). Genotype A HBsAg particles were not found to be O-glycosylated at all.
For exact allocation of the O-glycosylation site in natural HBsAg, two different strategies were used: (i) exhaustive digestion of the glycopeptide with carboxypeptidases in conjunction with MALDI-TOF-MS and (ii) tandem mass spectrometry. Only the latter technique unambiguously revealed a specific substitution at Thr-37. This is in agreement with data from Werr & Prange (1998) that M protein expressed in COS-7 cells is O-glycosylated between positions 27 and 47 of its amino acid sequence. Using the NetOGlyc 2.0 Prediction Server (Hansen et al., 1998) for prediction of potential O-glycosylation sites, for genotype D, Thr-37 had the highest score (Fig. 1c) , whereas, for genotype C, the highest probability was predicted at Thr-38. Thus, the assignments turned out to be correct in vivo only in the case of genotype D. Likewise, the data obtained by treatment with carboxypeptidases were misleading, since, for genotype C, results pointed to Thr-38 as the most likely glycosylation site, possibly due to steric hindrance and/or specific features of the peptide sequence. Tandem mass spectrometry with an ion-trap instrument not only allowed the assignment of the O-glycosylation site but also ensured a good coverage of the peptide sequence.
Exact quantitative estimation of the degree of M protein O-glycosylation is not possible since unglycosylated peptides 19-48 may be derived from both M and L proteins. Preliminary analyses of pre-S2-derived (glyco)peptides from M protein, isolated by preparative SDS-PAGE and in situ trypsin digestion, similarly revealed the presence of unglycosylated peptides 19-48, ruling out a complete O-glycosylation of this protein for genotype D (data not shown).
Since Thr-37, embedded in a sequence context favourable for O-glycosylation, is highly conserved in the pre-S2 domains of HBV genotypes B-F, in all primate hepatitis B virus genomes (Bartholomeusz & Schaefer, 2004) including the virus from the New World woolly monkey (Lanford et al., 1998) and even in the otherwise highly divergent pre-S2 sequence of WHV, respective threonine residues might be similarly glycosylated. The O-glycosylation at Thr-37 of pre-S2, however, cannot be essential for HBV genotype A, which exhibits no Thr within the range from aa 32 to 55, but contains numerous Ser residues in this region, which, as shown in this study, are not O-glycosylated.
Remarkable was the detection of O-glycan in L protein. This finding suggests that the post-translational translocation of its internal pre-S domain to the surface occurs at a site where O-glycosylation is possible, probably in the Golgi apparatus before secretion. Previously, we reported that the pre-S can be translocated at a mildly acidic pH in vitro (Bruss et al., 1994) . Such conditions may possibly also occur in vivo during export of HBsAg particles. Due to the small amounts of L protein, a more accurate analysis of the O-glycan in the L proteins was not possible.
Although the number or structures of the O-glycan(s) occurring in M protein expressed in rodent cell culture (Werr & Prange, 1998) has not been investigated so far, the size increase of this protein, as evidenced by SDS-PAGE, was significantly larger than expected for the type of Olinked side chain described here. Likewise, the increase in size, due to O-glycosylation, was higher for WHV than for HBV M protein (Tolle et al., 1998) . From these data, it may be concluded that O-glycanic substituents exist in rodent cell-derived M proteins in larger numbers and/or as enlarged structures. Consequently, the carbohydrate contents of the pre-S2 domains in the two studied genotype D (Jungers et al., 1994; Young et al., 2001) vaccines may be higher than in natural M proteins, which may cause lower immunogenicity (DeWilde et al., 1991) . Recently, two pre-S2 deletion variants of genotype C have been identified in human hepatocellular carcinoma patients, which showed a reduced HBsAg secretion. The secreted portion of HBsAg contained a larger 'hypermodified' M protein (Tai et al., 2002) , the nature of which is most likely extensive O-glycosylation, whereas the intracellular M protein had the expected size of the polypeptide without O-gylcosylation (P.-C. Tai, P. K. Chua, W. H. Gerlich and C. Shih, unpublished) . In their studies on M protein (genotype D), Werr & Prange (1998) also found expression in COS cells, the secreted portion of the protein to be Oglycosylated, whereas the intracellular portion was smaller and not O-gylcosylated. Thus, O-glycosylation may support secretion of certain HBV genotypes or variants.
